This text module covers the current prevalence and impact of inflammatory bowel disease (IBD), how to integrate treat to target into one’s practice, and data on several emerging TL1A inhibitors and the promise they pose in transforming the IBD treatment landscape.
Nurse Practitioners/Nurses: 0.75 Nursing contact hour
Physician Assistants/Physician Associates: 0.75 AAPA Category 1 CME credit
Physicians: maximum of 0.75 AMA PRA Category 1 Credit™
Released: May 08, 2025 | Expiration: May 07, 2026
Learning objectives:
Upon completion of this activity, participants should be able to:
- Detail available and emerging biomarkers and diagnostics informing treatment decisions in IBD
- Incorporate available biomarkers appropriately into clinical practice based on guideline recommendations and expert consensus
- Evaluate evidence for the utility of TL1A blockade in IBD treatment
Faculty:
Jordan E. Axelrad, MD, MPH, FACG
Co-Director, Inflammatory Bowel Disease Center at NYU Langone Health
Associate Professor of Medicine
NYU Grossman School of Medicine
New York, New York
Supporters
This activity is supported through an independent educational grant from Merck & Co., Inc., Rahway, NJ, USA.
Sponsor:
Provided by Clinical Care Options, LLC in partnership with the American Gastroenterological Association (AGA)
The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:
Primary Author
Jordan E. Axelrad, MD, MPH, FACG: consultant/advisor/speaker: AbbVie, Abviax, Adiso, bioMérieux, Bristol Myers Squibb, Celltrion, Ferring, Fresenius, Janssen, Merck, Pfizer, Vedanta; researcher: BioFire Diagnostics, Genentech, Janssen.
The planners and content peer reviewers from Clinical Care Options, LLC and the American Gastroenterological Association (AGA) do not have any relevant financial relationships to disclose.
